Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease

Darrell E White,1 Yang Zhao,2 Hemalatha Jayapalan,3 Pattabhi Machiraju,3 Ramu Periyasamy,3 Abayomi Ogundele2 1SkyVision Centers, Westlake, OH, USA; 2Medical Affairs, Sun Pharmaceutical Industries, Princeton, NJ, USA; 3Medical Services, Indegene, Inc, Bangalore, IndiaCorrespondence: Abayomi OgundeleM...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	physician satisfaction dry eye disease cyclosporine lifitegrast ocular surface Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8db4b64bb83a47058d929b6e1e983ae5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8db4b64bb83a47058d929b6e1e983ae5
record_format	dspace
spelling	oai:doaj.org-article:8db4b64bb83a47058d929b6e1e983ae52021-12-02T08:32:49ZPhysician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease1177-5483https://doaj.org/article/8db4b64bb83a47058d929b6e1e983ae52020-03-01T00:00:00Zhttps://www.dovepress.com/physician-satisfaction-with-anti-inflammatory-topical-medications-for--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Darrell E White,1 Yang Zhao,2 Hemalatha Jayapalan,3 Pattabhi Machiraju,3 Ramu Periyasamy,3 Abayomi Ogundele2 1SkyVision Centers, Westlake, OH, USA; 2Medical Affairs, Sun Pharmaceutical Industries, Princeton, NJ, USA; 3Medical Services, Indegene, Inc, Bangalore, IndiaCorrespondence: Abayomi OgundeleMedical Affairs, Sun Pharmaceutical Industries, Inc, 2 Independence Way, Princeton, NJ 08540, USAEmail abayomi.ogundele@sunpharma.comPurpose: Dry eye disease (DED) is one of the most common ophthalmic disorders. Pathogenesis of the disease includes inflammation of the ocular surface and lacrimal gland. Two anti-inflammatory prescription treatments are currently available: cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast 5% ophthalmic solution (LIF). The objective of this survey-based study was to assess physician satisfaction with CYC and LIF for the treatment of DED.Methods: Physicians currently treating DED patients with CYC or LIF were asked to rate the experiences of their patients currently or formerly using CYC and LIF, and their own perspectives on the two treatments.Results: Twenty-one physicians participated in the survey, providing responses on behalf of 210 patients. Overall, physicians reported low levels of satisfaction with onset of action of CYC and LIF, and fewer than half considered either drug to be effective in managing symptoms or improving patient quality of life (QoL). Burning sensation and dysgeusia were the most frequently reported side effects. Onset of action and effectiveness after onset were the main switching drivers. Although two-thirds of physicians were satisfied with the overall effectiveness of CYC and LIF, all physicians agreed that more DED treatment options are needed, with > 50% strongly agreeing.Conclusion: Physicians perceived a gap in DED management with currently available topical anti-inflammatory agents. Although satisfaction with CYC and LIF was high, few physicians considered these medications to be effective in managing symptoms or improving QoL.Keywords: physician satisfaction, dry eye disease, cyclosporine, lifitegrast, ocular surfaceWhite DEZhao YJayapalan HMachiraju PPeriyasamy ROgundele ADove Medical Pressarticlephysician satisfactiondry eye diseasecyclosporinelifitegrastocular surfaceOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 931-938 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	physician satisfaction dry eye disease cyclosporine lifitegrast ocular surface Ophthalmology RE1-994
spellingShingle	physician satisfaction dry eye disease cyclosporine lifitegrast ocular surface Ophthalmology RE1-994 White DE Zhao Y Jayapalan H Machiraju P Periyasamy R Ogundele A Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
description	Darrell E White,1 Yang Zhao,2 Hemalatha Jayapalan,3 Pattabhi Machiraju,3 Ramu Periyasamy,3 Abayomi Ogundele2 1SkyVision Centers, Westlake, OH, USA; 2Medical Affairs, Sun Pharmaceutical Industries, Princeton, NJ, USA; 3Medical Services, Indegene, Inc, Bangalore, IndiaCorrespondence: Abayomi OgundeleMedical Affairs, Sun Pharmaceutical Industries, Inc, 2 Independence Way, Princeton, NJ 08540, USAEmail abayomi.ogundele@sunpharma.comPurpose: Dry eye disease (DED) is one of the most common ophthalmic disorders. Pathogenesis of the disease includes inflammation of the ocular surface and lacrimal gland. Two anti-inflammatory prescription treatments are currently available: cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast 5% ophthalmic solution (LIF). The objective of this survey-based study was to assess physician satisfaction with CYC and LIF for the treatment of DED.Methods: Physicians currently treating DED patients with CYC or LIF were asked to rate the experiences of their patients currently or formerly using CYC and LIF, and their own perspectives on the two treatments.Results: Twenty-one physicians participated in the survey, providing responses on behalf of 210 patients. Overall, physicians reported low levels of satisfaction with onset of action of CYC and LIF, and fewer than half considered either drug to be effective in managing symptoms or improving patient quality of life (QoL). Burning sensation and dysgeusia were the most frequently reported side effects. Onset of action and effectiveness after onset were the main switching drivers. Although two-thirds of physicians were satisfied with the overall effectiveness of CYC and LIF, all physicians agreed that more DED treatment options are needed, with > 50% strongly agreeing.Conclusion: Physicians perceived a gap in DED management with currently available topical anti-inflammatory agents. Although satisfaction with CYC and LIF was high, few physicians considered these medications to be effective in managing symptoms or improving QoL.Keywords: physician satisfaction, dry eye disease, cyclosporine, lifitegrast, ocular surface
format	article
author	White DE Zhao Y Jayapalan H Machiraju P Periyasamy R Ogundele A
author_facet	White DE Zhao Y Jayapalan H Machiraju P Periyasamy R Ogundele A
author_sort	White DE
title	Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
title_short	Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
title_full	Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
title_fullStr	Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
title_full_unstemmed	Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
title_sort	physician satisfaction with anti-inflammatory topical medications for the treatment of dry eye disease
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/8db4b64bb83a47058d929b6e1e983ae5
work_keys_str_mv	AT whitede physiciansatisfactionwithantiinflammatorytopicalmedicationsforthetreatmentofdryeyedisease AT zhaoy physiciansatisfactionwithantiinflammatorytopicalmedicationsforthetreatmentofdryeyedisease AT jayapalanh physiciansatisfactionwithantiinflammatorytopicalmedicationsforthetreatmentofdryeyedisease AT machirajup physiciansatisfactionwithantiinflammatorytopicalmedicationsforthetreatmentofdryeyedisease AT periyasamyr physiciansatisfactionwithantiinflammatorytopicalmedicationsforthetreatmentofdryeyedisease AT ogundelea physiciansatisfactionwithantiinflammatorytopicalmedicationsforthetreatmentofdryeyedisease
_version_	1718398499342516224

Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease

Ejemplares similares